866-997-4948(US-Canada Toll Free)

Colon Carcinoma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Oncology

No. of Pages : 34 Pages


Global Markets Directs, \'Colon Carcinoma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Colon Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Carcinoma. Colon Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Colon Carcinoma.
  • A review of the Colon Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Colon Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Colon Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Colon Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Colon Carcinoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Colon Carcinoma 7
Colon Carcinoma Therapeutics under Development by Companies 9
Colon Carcinoma Therapeutics under Investigation by Universities/Institutes 10
Discovery and Pre-Clinical Stage Products 11
Comparative Analysis 11
Colon Carcinoma Therapeutics - Products under Development by Companies 12
Colon Carcinoma Therapeutics - Products under Investigation by Universities/Institutes 13
Companies Involved in Colon Carcinoma Therapeutics Development 14
AIMM Therapeutics B.V. 14
PepTx, Inc. 15
Colon Carcinoma - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
CIGB-247 Vaccine - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
PTX-001 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
P-900 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
P-732 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
PTX-004 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Antibodies For Gastrointestinal Diseases - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Anti-EGFR-ATEP - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Methoxynaphthylfenoterol - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Salmonella Based Cancer Vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Colon Carcinoma Therapeutics - Dormant Products 32

Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Table


Number of Products Under Development for Colon Carcinoma, H2 2013 7
Products under Development for Colon Carcinoma - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 13
AIMM Therapeutics B.V., H2 2013 14
PepTx, Inc., H2 2013 15
Assessment by Monotherapy Products, H2 2013 16
Assessment by Stage and Route of Administration, H2 2013 18
Assessment by Stage and Molecule Type, H2 2013 20
Colon Carcinoma Therapeutics - Dormant Products 32

List of Chart


Number of Products under Development for Colon Carcinoma, H2 2013 7
Products under Development for Colon Carcinoma - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Discovery and Pre-Clinical Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 16
Assessment by Route of Administration, H2 2013 17
Assessment by Stage and Route of Administration, H2 2013 18
Assessment by Molecule Type, H2 2013 19
Assessment by Stage and Molecule Type, H2 2013 20

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *